Want to see IN:MEDANTA full AI Analyst Report?
MEDANTA Stock Chart & Stats
₹1370.40
₹36.20(2.64%)
At close: 4:00 PM EDT
₹1370.40
₹36.20(2.64%)
Day’s Range― - ―
52-Week Range₹955.20 - ₹1,455.85
Previous CloseN/A
Volume320.04K
Average Volume (3M)17.50K
Market Cap
₹380.61B
Enterprise Value₹350.31K
Total Cash (Recent Filing)₹11.30B
Total Debt (Recent Filing)₹11.90B
Price to Earnings (P/E)67.9
Beta0.69
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.04%
Share Statistics
EPS (TTM)20.71
Shares Outstanding268,871,800
10 Day Avg. Volume39,597
30 Day Avg. Volume17,497
Financial Highlights & Ratios
PEG Ratio2.98
Price to Book (P/B)6.52
Price to Sales (P/S)5.86
P/FCF Ratio-114.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,500.00Price Target Upside9.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)25.77
Revenue Forecast (FY)₹51.86B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue & Earnings GrowthMulti-year revenue and net income growth indicates durable demand for tertiary/quaternary services and successful capacity utilization. Sustained double-digit top-line growth supports long-term margin expansion potential and funds strategic reinvestment in high-acuity specialties.
Integrated Multi-specialty Hospital NetworkA vertically integrated hospital model—combining inpatient, outpatient, diagnostics, pharmacies and ancillaries—creates higher per-patient revenue capture and referral stickiness. This structural footprint supports cross-selling, higher lifetime patient value and defensible market position.
Improved Operating Cash Generation & ROEStronger operating cash flows and healthy ROE signal effective capital deployment and core cash-generative operations. Over time this underpins sustainable investment capacity and the ability to support network expansion or clinical capability upgrades without purely relying on external capital.
Bears Say
Negative Free Cash Flow In 2026A swing to negative free cash flow reflects elevated capex or working capital needs and reduces near-term financial flexibility. If sustained, it may force external funding, delay discretionary investments, or constrain returns despite underlying operating profitability.
Rising Total Debt In 2026An uptick in debt after prior deleveraging raises interest and refinancing risk and could pressure covenants or free cash flow coverage. Persistent higher leverage would limit balance-sheet optionality for growth or acquisitions and increase sensitivity to rate moves.
Payer-mix And Reimbursement ExposureReliance on a mix of self-pay, private insurers and government schemes creates structural variability in realizations and collection lags. Adverse reimbursement changes or slower settlements can compress margins and elevate working-capital needs across multi-month cycles.
Global Health Limited News
MEDANTA FAQ
What was Global Health Limited’s price range in the past 12 months?
Global Health Limited lowest stock price was ₹955.20 and its highest was ₹1455.85 in the past 12 months.
What is Global Health Limited’s market cap?
Global Health Limited’s market cap is ₹380.61B.
When is Global Health Limited’s upcoming earnings report date?
Global Health Limited’s upcoming earnings report date is Nov 06, 2026 which is in 97 days.
How were Global Health Limited’s earnings last quarter?
Global Health Limited released its earnings results on Jul 30, 2026. The company reported ₹5.906 earnings per share for the quarter, beating the consensus estimate of ₹5.41 by ₹0.496.
Is Global Health Limited overvalued?
According to Wall Street analysts Global Health Limited’s price is currently Undervalued.
Does Global Health Limited pay dividends?
Global Health Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of 0.04%. See more information on Global Health Limited dividends here
What is Global Health Limited’s EPS estimate?
Global Health Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Global Health Limited have?
Global Health Limited has 268,871,800 shares outstanding.
What happened to Global Health Limited’s price movement after its last earnings report?
Global Health Limited reported an EPS of ₹5.906 in its last earnings report, beating expectations of ₹5.41. Following the earnings report the stock price went down -1.187%.
Which hedge fund is a major shareholder of Global Health Limited?
Currently, no hedge funds are holding shares in IN:MEDANTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Global Health Limited
Operating throughout India, Global Health Limited, known by its Medanta brand, stands as a prominent multi-specialty tertiary care provider. The company delivers a comprehensive suite of healthcare services, with particular expertise in cardiology, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplantation, as well as kidney and urology treatments. Established in 2004 and headquartered in Gurgaon, India, it operates a network of four hospitals strategically located in Gurugram, Indore, Ranchi, and Lucknow.
MEDANTA Stock 12 Month Forecast
Average Price Target
₹1,500.00
▲(9.46% Upside)
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Narayana Hrudayalaya Ltd.
―






